Namoline 

Namoline, a γ-pyrone, is a selective and reversible Lysine-specific demethylase 1 (LSD1) inhibitor with an IC50 of 51 μM in a HRP-coupled enzymatic assay. Namoline impairs LSD1 demethylase activity and blocks cell proliferation. Namoline has the potential for androgen-dependent prostate cancer research^[1].

Namoline (50 μM; 24, 48, 72 hours) reduces androgen-induced proliferation of LNCaP cells^[1].
Namoline (50 μM) specifically impairs AR agonist R1881-induced (1 nM) demethylation of H3K9me1 and H3K9me2 in LNCaP cells^[1].
Namoline (50 μM) does not affect the enzymatic activities of MAOs under these conditions^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Namoline (0.02 mg;ip; daily) severely blunts xenograft tumor growth in nude mice with LNCaP cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

293.58

C₁₀H₃ClF₃NO₄

342795-11-3

O=C1C(Cl)=C(C(F)(F)F)OC2=CC=C([N+]([O-])=O)C=C12

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Dominica Willmann, et al. Impairment of prostate cancer cell growth by a selective and reversible lysine-specific demethylase 1 inhibitor. Int J Cancer. 2012 Dec 1;131(11):2704-9.  [Content Brief]